Gética 2020

36 VI FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER cytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncology 2016;2(10):1354. 7. Stanton SE, Disis ML. Clinical significance of tumor-infil- trating lymphocytes in breast cancer. Journal for Immu- noTherapy of Cancer 2016;4:59. 8. Salgado R, Loi S. Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. The Lancet Oncology 2018;19(1):3-5. 9. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast can- cer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26(2):259-71. 10. Loi S, Drubay D, Adams S, et al. Tumor-Infiltrating Lym- phocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol 2019;37(7):559-69. Disponible en: http:// ascopubs.org/doi/pdf/10.1200/JCO.18.01010 11. Park JH, Jonas SF, Bataillon G, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with ear- ly-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol 2019;30(12):1941-9. Disponible en: https://academic. oup.com/annonc/advance-article/doi/10.1093/an- nonc/mdz395/5575078 12. Gruosso T, Gigoux M, ManemVSK, et al. Spatially distinct tumor immune microenvironments stratify triple-nega- tive breast cancers. J Clin Invest 2019;129(4):1785-800. 13. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heteroge- neous disease. Nat Rev Clin Oncol 2016;13(11):674-90. 14. Fernández-Martínez A, Tanioka M, Fan C, et al. Predic- tive and prognostic value of B-cell gene-expression sig- natures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance). Ann Oncol 2019;30:v55. 15. Iglesia MD, Parker JS, Hoadley KA, et al. Genomic Anal- ysis of Immune Cell Infiltrates Across 11 Tumor Types. JNCI 2016;108(11):djw144. 16. Haricharan S, Bainbridge MN, Scheet P, et al. Somatic mu- tation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 2014;146(1):211-20. 17. Chan TA, Yarchoan M, Jaffee E, et al. Development of tu- mor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019;30(1):44-56. 18. Alexandrov LB, Kim J, Haradhvala NJ, et al. PCAWG Mu- tational Signatures Working Group, PCAWG Consor- tium. The repertoire of mutational signatures in human cancer. Nature 2020;578(7793):94-101. 19. Morganella S, Alexandrov LB, Glodzik D, et al. The topog- raphy of mutational processes in breast cancer genomes. Nat Commun 2016;7:11383. Disponible en: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC5001788/ 20. Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvi- ronment in primary and metastatic breast carcinomas. Human Pathology 2016;47(1):52-63. 21. Schalper KA, Velcheti V, Carvajal D, et al. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clin Cancer Res 2014;20(10):2773-82. 22. Buisseret L, Garaud S, de Wind A, et al. Tumor-infiltrat- ing lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoim- munology 2016;6(1):e1257452. Disponible en: https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC5283629/ 23. De la Cruz-Merino L, Chiesa M, Caballero R, et al. Chapter One - Breast Cancer Immunology and Im- munotherapy: Current Status and Future Perspec- tives. En: Galluzzi L, editor. International Review of Cell and Molecular Biology. Cambridge, Massachu- setts: Academic Press; 2017. pp. 1-53. Disponible en: http://www.sciencedirect.com/science/article/pii/ S1937644816301034 24. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Can- cer. New Engl J Med 2018;379(22):2108-21. 25. Schmid P, Adams S, Rugo HS, et al. IMpassion130: up- dated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previ- ously untreated locally advanced or metastatic tri- ple-negative breast cancer (mTNBC). JCO 2019;37(Sup- pl.15):1003-1003. 26. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2020;21(1):44-59. 27. Cortés J, Lipatov O, Im S-A, et al. LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastat- ic triple negative breast cancer (mTNBC). Ann On- col 2019;30(Suppl.5). Disponible en: https://aca- demic.oup.com/annonc/article/30/Supplement_5/ mdz394.010/5577706 28. Tolaney SM, Barroso-Sousa R, Keenan T, et al. Ran- domized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone recep- tor-positive (HR+) metastatic breast cancer (MBC). JCO 2019;37(Suppl.15):1004-1004. 29. Shah AN, Flaum LE, Rademaker A, et al. A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative en- docrine-refractory metastatic breast cancer (MBC). JCO 2019;37(Suppl.15):1096-1096. 30. Emens LA, Esteva FJ, Beresford M, et al. Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastu- zumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Ann Oncol 2019;30:v104. 31. Emens LA, Esteva F, Beresford M, et al. Abstract PD3- 01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC). Cancer Res 2019;79(Sup- pl.4):PD3-01-PD3-01. 32. Emens LA, Middleton G. The Interplay of Immunothera- py and Chemotherapy: Harnessing Potential Synergies. Cancer Immunol Res 2015;3(5):436-43.